Share on

Middle East and Africa Cancer Metabolism Based Therapeutics Market Research Report – Segmented By Therapy, Drug Type, Indication & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 7871
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the Middle East and Africa Cancer Metabolism Based Therapeutics Market is forecasted to grow at a sluggish rate between 2022 to 2027.  

Cancer metabolism is a term used to describe the differences in cellular metabolism pathways present in cancer cells compared to normal tissue cells. In medicine, therapeutic refers to the art and science of healing and the discipline of medicine that deals with the treatment of certain diseases. On the other hand, therapeutics refers to the technique of delivery and the use of pharmaceuticals in the treatment of illness.

The metabolic activity in malignant tissue increases the quantity of lactate produced from glucose by a factor of ten in aerobic conditions. This result sparked widespread interest, prompting market players to focus on metabolic pathways searching for cancer-curable elements.  Cancer metabolism is based on cancer cells, which modify glutamine and glucose metabolism for nucleotides, lipids, proteins, and fatty acids, which aids in the growth of cancer cells. Most notably, the targeting cancer metabolism issue could lead to the development of novel medications to treat a variety of cancers. In addition, rising cancer rates are likely to drive the market for cancer metabolism-based therapeutics in the Middle East and Africa.

The rising incidence of cancer, the development of advanced therapies, and the commercialization of biosimilars are other significant factors propelling the MEA cancer medications market forward. In addition, the market is being driven by novel drugs that are being precisely created to target blocking metabolic pathways and key enzymes involved in cancer cell metabolism.

However, failure would limit market expansion due to the high expenses of developing new medications and the risk of adverse effects connected with cancer treatment therapies.

This research report on the Middle East and Africa cancer metabolism-based therapeutics market has been segmented & sub-segmented into the following categories:

By Therapy:

  • Biological Drug Therapies  
  • Targeted Drug Therapies  

By Drug Type:

  • Enasidenib              
  • CPI-613    
  • Other Drugs      

By Indication:

  • Melanoma              
  • Myelodysplastic Syndrome (MDS)
  • Acute Myeloid Leukemia (AML)    
  • Metastatic Renal Cell Carcinoma    
  • Others     

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East and Africa regional markets are expected to account for a modest portion of the worldwide market. Mutations in oncogenes and cell signaling pathways are frequently responsible for changes in metabolic processes in cancer cells. However, now that specific enzymes within each metabolic pathway have been identified, it is expected that medications targeting these enzymes will have a high efficacy in treating cancer while having low side effects.

Countries like UAE and South Africa occupy a significant share in the MEA cancer metabolism-based therapeutics market.

KEY MARKET PLAYERS:

Some prime manufacturers of Cancer Metabolism Based Therapeutics in the Middle East and Africa are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample